Vimarsana
Biggest News Aggregation in the World

Jin Long Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jin Long Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jin Long Chen Today - Breaking & Trending Today

NGM Stock Price | NGM Biopharmaceuticals Inc. Stock Quote (U.S.: Nasdaq) - Vimarsana News

NGM Stock Price | NGM Biopharmaceuticals Inc. Stock Quote (U.S.: Nasdaq)

NGM | Complete NGM Biopharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

NGM Bio lays off a third of its workforce in 'difficult' decision - Vimarsana News

NGM Bio lays off a third of its workforce in 'difficult' decision

BioPharma

NGM Biopharmaceuticals, Inc. to Post FY2023 Earnings of ($1.79) Per Share, B. Riley Forecasts (NASDAQ:NGM) - Vimarsana News

NGM Biopharmaceuticals, Inc. to Post FY2023 Earnings of ($1.79) Per Share, B. Riley Forecasts (NASDAQ:NGM)

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) – Analysts at B. Riley reduced their FY2023 EPS estimates for shares of NGM Biopharmaceuticals in a research note issued to investors on Wednesday, March 29th. B. Riley analyst M. Mamtani now expects that the company will earn ($1.79) per share for the year, down from their previous […]

April 4, 2023 Subject Line: Important Business Updates - Form 8-K - Vimarsana News

April 4, 2023 Subject Line: Important Business Updates - Form 8-K

April 4, 2023 Subject Line: Important Business Updates Dear Explorers: This morning I am announcing a difficult, but necessary,... | April 4, 2023

Morgan Stanley Raises Endeavour Mining (OTCMKTS:EDVMF) Price Target to C$36.00 - Vimarsana News

Morgan Stanley Raises Endeavour Mining (OTCMKTS:EDVMF) Price Target to C$36.00

NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its price target decreased by B. Riley from $8.00 to $7.00 in a research note issued to investors on Thursday, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, Q2 […]